На этой странице перечислены больницы направления «Кардиоторакальная и сосудистая хирургия» (включая Coronary Artery Disease Treatment) в Ченнаи, Индия, включая Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital и другие.
Спросите нас о «Coronary Artery Disease Treatment» в Ченнаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 8 аккредитованных больниц (Кардиоторакальная и сосудистая хирургия) в Ченнаи, Индия
Рекомендуем🇮🇳 Apollo Hospitals, Greams Road
Больница занимает 1-е место в этом списке по указанному рейтингу (4.7/5, 125 отзывов).
🇮🇳 Gleneagles Global Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 112 отзывов).
🇮🇳 Dr. Rela Institute and Medical Centre
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 108 отзывов).
🇮🇳 SIMS Hospital
Больница занимает 4-е место в этом списке по указанному рейтингу (4.6/5, 20 отзывов).
🇮🇳 Sankara Nethralaya
Больница занимает 5-е место в этом списке по указанному рейтингу (4.4/5, 220 отзывов).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Больница занимает 6-е место в этом списке по указанному рейтингу (4.4/5, 76 отзывов).
🇮🇳 MIOT International
Больница занимает 7-е место в этом списке по указанному рейтингу (4.4/5, 200 отзывов).
🇮🇳 MGM Healthcare
Больница занимает 8-е место в этом списке по указанному рейтингу (3.7/5, 34 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Кардиоторакальная и сосудистая хирургия» указано среди её специализаций и она находится в Ченнаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «coronary artery disease treatment» в Ченнаи, Индия?
Выбор подходящей больницы для «coronary artery disease treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Кардиоторакальная и сосудистая хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Coronary Artery Disease Treatment»
Coronary artery disease (CAD) — the leading cause of global cardiovascular mortality — is treated with interventional, surgical, and pharmacological strategies that restore myocardial perfusion and prevent adverse cardiac events; high-volume cardiac centres in India and the UAE report procedural success rates exceeding 95% for percutaneous coronary intervention (PCI) and 98% operative survival for elective coronary artery bypass grafting (CABG). GAF Healthcare partners exclusively with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed institutions in Dubai and Abu Dhabi, giving international patients access to world-class cardiologists and cardiac surgeons at a fraction of Western costs, with end-to-end concierge support from first inquiry through post-discharge follow-up. Hospital Stay: 3–7 days (PCI: 2–3 days; CABG: 5–7 days) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (PCI patients cleared at 2–3 weeks; CABG patients at 4–6 weeks, subject to cardiologist sign-off and negative DVT assessment) • Success Rate: 95–98% procedural success (PCI); 97–98% operative survival (elective CABG)
Clinical Overview
Coronary artery disease is a chronic atherosclerotic condition characterised by the progressive accumulation of lipid-rich plaques within the intima of the epicardial coronary arteries, leading to luminal narrowing, reduced myocardial oxygen delivery, and — when plaques rupture — acute thrombotic occlusion resulting in ST-elevation or non-ST-elevation myocardial infarction. The haemodynamic consequences of significant stenosis (≥70% luminal reduction, or fractional flow reserve ≤0.80) include demand-supply mismatch during exertion (stable angina), resting ischaemia in more advanced disease, ventricular remodelling, systolic dysfunction, and ultimately heart failure if left untreated. Risk amplifiers such as Type 2 diabetes, dyslipidaemia, hypertension, chronic kidney disease, and smoking accelerate plaque burden and confer a substantially higher MACE (major adverse cardiovascular events) risk. Contemporary diagnosis integrates clinical scoring (HEART Score, GRACE Score, TIMI Score), non-invasive functional imaging — including stress echocardiography, SPECT myocardial perfusion imaging, cardiac MRI with gadolinium-based late enhancement, and CT coronary angiography (CTCA) with fractional flow reserve derived from CT (FFR-CT) — and invasive coronary angiography with physiological wire-based assessment (FFR, iFR, RFR) to stratify lesion significance before revascularisation decisions are made. The SYNTAX Score, EuroSCORE II, and STS Risk Calculator are routinely applied by multidisciplinary Heart Teams to determine the optimal revascularisation strategy: percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or optimised medical therapy (OMT) alone. The standard of care at GAF Healthcare's partner institutions mirrors international guidelines (ESC 2023, ACC/AHA 2021). Guideline-directed medical therapy (GDMT) forms the pharmacological backbone in all patients and includes high-intensity statins (rosuvastatin/atorvastatin), dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor — ticagrelor or prasugrel — for ACS or post-PCI), ACE inhibitors or ARNIs (sacubitril/valsartan) for reduced ejection fraction, beta-blockers, SGLT-2 inhibitors (empagliflozin/dapagliflozin) for their proven cardioprotective benefit, and GLP-1 receptor agonists where indicated. Revascularisation is layered on top of GDMT based on symptom burden, ischaemic territory, lesion complexity, and left ventricular function.
Who is a Candidate?
• ELIGIBLE PATIENTS (PCI / CABG): • Stable CAD with significant single-, double-, or triple-vessel disease (FFR ≤0.80 or angiographic stenosis ≥70%) refractory to optimal medical therapy • Acute coronary syndromes (STEMI, NSTEMI, unstable angina) requiring urgent or early invasive strategy • Left main coronary artery disease (LMCA stenosis ≥50%) — Heart Team decision between PCI and CABG based on SYNTAX Score • SYNTAX Score ≤22: PCI is preferred for multivessel disease • SYNTAX Score 23–32: equipoise; individualised Heart Team decision • SYNTAX Score ≥33: CABG preferred (superior long-term outcomes demonstrated in SYNTAX, FREEDOM, and NOBLE trials) • Patients with diabetes mellitus and multivessel CAD: CABG strongly preferred (FREEDOM trial data) • Reduced LVEF (EF <35%) with viable myocardium on PET/MRI viability imaging indicating potential functional recovery post-revascularisation • Silent ischaemia with objective evidence of large ischaemic burden (>10% of LV myocardium) on stress imaging • REQUIRED DIAGNOSTIC WORKUP PRIOR TO TRAVEL: • Resting 12-lead ECG and 24-hour Holter monitor • Transthoracic echocardiogram (TTE/ECHO) with LVEF assessment • Coronary CT angiography (CTCA) with or without FFR-CT (if invasive angiography not yet performed) • Stress test: treadmill, stress echo, or myocardial perfusion SPECT/PET • Cardiac MRI with late gadolinium enhancement for viability assessment (where LVEF is reduced) • Full blood panel: CBC, renal function (eGFR), HbA1c, fasting lipid panel, coagulation profile (INR/aPTT), BNP/NT-proBNP • Carotid Doppler ultrasound (mandatory pre-CABG) • Peripheral vascular assessment if conduit harvesting (saphenous vein, radial artery) planned • Pulmonary function tests (pre-CABG) • CONTRAINDICATIONS / HIGH-RISK CONSIDERATIONS: • Active systemic infection or sepsis (elective procedure must be deferred) • Severe uncorrected coagulopathy or active major bleeding • Contrast allergy without adequate pre-medication protocol • eGFR <15 mL/min/1.73m² — requires nephrology optimisation and may indicate off-pump CABG preference • Severe, irreversible non-ischaemic cardiomyopathy where revascularisation offers no benefit • High perioperative surgical risk: EuroSCORE II >10% or STS predicted mortality >8% — requires careful Heart Team deliberation, possible alternative (TAVI paradigm-equivalent; consider TMVr if concurrent MR) • Haemodynamic instability requiring mechanical circulatory support stabilisation prior to elective transfer
Treatment Options & Approaches
PHARMACOLOGICAL (OPTIMISED MEDICAL THERAPY — OMT): All CAD patients receive evidence-based pharmacotherapy regardless of revascularisation strategy. Core agents include: high-intensity statins targeting LDL-C <55 mg/dL (ESC 2023 goal for very high-risk patients); PCSK9 inhibitors (evolocumab, alirocumab) for statin-intolerant or refractory hyperlipidaemia; dual antiplatelet therapy (DAPT) with aspirin 75–100 mg + ticagrelor 90 mg BD or prasugrel 10 mg OD post-ACS/PCI; beta-blockers (bisoprolol, metoprolol succinate); ACE inhibitors or sacubitril/valsartan (ARNi) for EF <40%; SGLT-2 inhibitors (empagliflozin, dapagliflozin) for cardioprotection and HF risk reduction; ranolazine or ivabradine for persistent angina on maximal therapy; colchicine 0.5 mg OD for residual inflammatory risk (LoDoCo2 evidence). PERCUTANEOUS CORONARY INTERVENTION (PCI): • Standard PCI: Radial-access preferred (reduced MACE and bleeding vs. femoral; MATRIX trial data); 6F or 7F guiding catheter; coronary angiography and real-time stenting under fluoroscopic guidance. • Drug-Eluting Stents (DES): Third-generation ultrathin-strut biodegradable-polymer DES (e.g., Orsiro, XIENCE Sierra, Resolute Onyx) are the current standard, with restenosis rates <5% at 1 year. • Intravascular Imaging-Guided PCI: Optical coherence tomography (OCT) and intravascular ultrasound (IVUS) are used routinely at partner centres to optimise stent sizing, apposition, and landing zones, reducing stent failure rates by 30–40% (ILUMIEN IV, OCTOBER trials). • Physiology-Guided PCI: FFR (fractional flow reserve) and instantaneous wave-free ratio (iFR) used to defer stenting of non-flow-limiting lesions, reducing unnecessary procedures. • Complex PCI Techniques: Rotational atherectomy (Rotablator) for heavily calcified lesions; orbital atherectomy; intravascular lithotripsy (IVL / Shockwave) for calcified nodules; chronic total occlusion (CTO) PCI using antegrade dissection/re-entry (ADR) and retrograde techniques — success rates >85% at high-volume centres. • Haemodynamic Support: Impella CP/5.5 or IABP utilised for high-risk PCI (unprotected LMCA, severely reduced EF). CORONARY ARTERY BYPASS GRAFTING (CABG): • Conventional On-Pump CABG: Median sternotomy with cardiopulmonary bypass (CPB) and cardioplegic arrest; remains gold standard for complex multivessel and LMCA disease. • Off-Pump CABG (OPCAB): Performed on the beating heart without CPB; reduces neurological complications and blood product use; preferred in patients with porcelain aorta, severe renal impairment, or high stroke risk. • Minimally Invasive Direct CABG (MIDCAB): Left anterior thoracotomy approach for LIMA-to-LAD grafting in isolated LAD disease; faster recovery, no sternotomy. • Totally Endoscopic CABG (TECAB): Robotic-assisted (da Vinci Surgical System) fully endoscopic CABG; available at select partner centres; 3–5 mm port incisions, significantly reduced recovery time and transfusion rates. • Hybrid Coronary Revascularisation (HCR): Combines robotic MIDCAB (LIMA-LAD) with same-sitting or staged PCI to non-LAD vessels — optimal for patients who benefit from arterial LIMA grafting to the LAD but are not ideal surgical candidates for full sternotomy. • Conduit Selection: Left internal mammary artery (LIMA) to LAD is the benchmark graft (10-year patency >90%); bilateral internal mammary arteries (BIMA) improve long-term survival but require careful selection (avoid in diabetics with poor wound healing); radial artery grafts; saphenous vein grafts (SVG) with contemporary no-touch harvesting technique improving 1-year patency. • Total Arterial Revascularisation: Increasingly performed at GAF partner centres for younger patients (<65 years) to maximise graft longevity. HYBRID AND STRUCTURAL INTERVENTIONS FOR CO-EXISTING PATHOLOGY: • Transcatheter Aortic Valve Replacement (TAVR/TAVI): When CAD coexists with severe aortic stenosis; concomitant or staged PCI + TAVI performed. • MitraClip / Transcatheter Mitral Valve Repair (TMVr): For ischaemic mitral regurgitation associated with CAD and reduced EF. • Renal Denervation: Considered adjunctively in CAD patients with resistant hypertension. • Enhanced External Counterpulsation (EECP): Non-invasive option for refractory angina in patients who are not revascularisation candidates; 35-session outpatient protocol.
Восстановление
PHASE 1 — PRE-TRAVEL CONSULTATION (Weeks 1–2 before departure): • GAF Healthcare coordinates a teleconsultation with the assigned interventional cardiologist or cardiac surgeon at the chosen partner centre. • All diagnostic records (angiogram images/DICOM files, ECHO report, stress test, blood work) are reviewed remotely. • A preliminary treatment plan — PCI vs. CABG vs. OMT — is confirmed by the multidisciplinary Heart Team. • Patient receives a personalised cost estimate, visa assistance, pre-travel medication guidance (antiplatelet continuation/bridging instructions), and travel insurance advisory. • GAF secures the hospital admission slot and arranges airport reception. PHASE 2 — ARRIVAL AND PRE-PROCEDURE ASSESSMENT (Days 1–2): • Airport pickup by GAF-assigned medical concierge; transfer to partner hospital or pre-booked accommodation. • Repeat baseline investigations on arrival: ECG, ECHO, renal panel, coagulation screen, CBC, chest X-ray. • Anaesthesiology and cardiac surgical pre-operative evaluation (for CABG candidates). • Invasive coronary angiography performed (if not done pre-travel) to finalise anatomy and SYNTAX Score. • Heart Team meeting (where applicable) to confirm revascularisation strategy. • Informed consent obtained; anaesthesia plan documented; NPO instructions given. PHASE 3 — THE PROCEDURE: • PCI (Duration: 45–90 minutes): Radial artery access; real-time coronary angiography; IVUS/OCT imaging; stent deployment with post-dilatation; haemostasis with radial compression band; patient transferred to cardiac care unit (CCU) for 12–24 hours monitoring. • CABG (Duration: 3–6 hours): General anaesthesia induction; median sternotomy or minimally invasive/robotic access; conduit harvesting; anastomosis construction; CPB weaning (if on-pump); chest closure; ICU admission for 24–48 hours intensive haemodynamic monitoring. PHASE 4 — IN-HOSPITAL RECOVERY: • PCI: CCU monitoring for 12–24 hours; radial site assessment; ambulation on Day 1; DAPT education; discharge typically Day 2–3 post-procedure. • CABG: ICU 24–48 hours → step-down cardiac ward; physiotherapy begins Day 2 (deep breathing exercises, early ambulation); chest drains removed Day 2–3; temporary pacing wires removed Day 4–5; sternum stability and wound assessment; discharge Day 5–7. • All patients: Repeat ECHO before discharge; medication reconciliation; cardiologist discharge summary provided. PHASE 5 — POST-DISCHARGE RECOVERY AND FIT-TO-FLY ASSESSMENT: • PCI patients: 7–10 days local rest recommended; outpatient cardiology review at Day 10–14; ECG and wound check; fit-to-fly assessment at 2–3 weeks post-PCI; compression stockings and DVT prophylaxis guidance for long-haul flight. • CABG patients: 2–3 weeks local convalescence at GAF-arranged serviced accommodation; cardiac rehabilitation sessions begin Day 7–10 (supervised by partner centre physiotherapist); repeat ECHO and wound review at Week 3; sternal precautions (no lifting >5 kg, no driving) for 6 weeks; fit-to-fly typically at 4–6 weeks post-CABG subject to cardiologist clearance and absence of pleural effusion or wound complication. • GAF Healthcare provides a detailed Fit-to-Fly certificate and a structured home-country handover document for the patient's local cardiologist. PHASE 6 — LONG-TERM FOLLOW-UP: • GAF coordinates remote follow-up teleconsultation at 1 month, 3 months, and 6 months post-discharge. • Statin, antiplatelet, and GDMT adherence monitoring via GAF digital health platform. • Annual stress imaging or CTCA to monitor graft patency (post-CABG) or in-stent restenosis (post-PCI).
Возможные риски
Coronary revascularisation is a high-acuity cardiovascular procedure and carries procedure-specific risks that must be transparently communicated to all patients. For PCI, recognised complications include coronary artery dissection or perforation (<1%), no-reflow phenomenon (2–5% in primary PCI for STEMI, less in elective), in-stent restenosis (3–7% with contemporary DES at 1 year), stent thrombosis (acute <24 hours, subacute 1–30 days, late >30 days; overall incidence <1% with optimal DAPT adherence), access-site haematoma or pseudoaneurysm (radial access reduces this to <1%), contrast-induced nephropathy (risk stratified by baseline eGFR; preventable with adequate pre-hydration and N-acetylcysteine), and radiation exposure. Rare but serious PCI complications include cardiac tamponade requiring pericardiocentesis and emergency CABG conversion (<0.5%). For CABG, risks include perioperative myocardial infarction (1–3%), stroke or neurological deficit (1–2% on-pump, lower with OPCAB), atrial fibrillation (25–40% post-CABG, usually self-limiting), wound infection including deep sternal wound infection (1–2%, higher in diabetics with BIMA), renal impairment (5–10%, usually transient), graft failure (SVG occlusion rate 15–20% at 1 year vs. LIMA <5% at 10 years), prolonged ventilation, bleeding requiring re-exploration (2–4%), and — in elderly or high-EuroSCORE patients — mortality risk as predicted by validated models. Long-haul air travel post-procedure carries DVT/PE risk; all patients travelling home after CABG at 4–6 weeks are prescribed low-molecular-weight heparin (LMWH) bridging and mandatory compression stockings as part of GAF Healthcare's travel safety protocol. Patients must maintain uninterrupted DAPT (particularly ticagrelor or prasugrel) in the weeks following PCI and must never self-discontinue antiplatelet therapy, as premature cessation is the single greatest risk factor for catastrophic stent thrombosis.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical support that removes every logistical barrier for international cardiac patients and their families. VISA ASSISTANCE — INDIA: GAF coordinates the e-Medical Visa application (available to citizens of 156+ eligible countries) through India's official online portal. The process requires a letter of invitation from the partner hospital, patient passport details, and the GAF case reference number. e-Medical Visas are typically approved within 72 hours, are valid for 60 days, and allow two extensions of 60 days each — sufficient for the most complex CABG recovery. A companion/attendant e-Medical Visa is simultaneously arranged for one family member at no extra GAF service fee. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of 56 countries (GCC nationals, US, UK, EU, Australia, Canada, and others) receive visa-free or visa-on-arrival access to the UAE. For nationalities requiring a prior visa, GAF coordinates a medical treatment visa application through the UAE Federal Authority for Identity, Citizenship, Customs and Port Security (ICP) in partnership with the DHA-licensed hospital. UAE medical visas are typically processed within 5–10 working days. AIRPORT TRANSFERS AND GROUND LOGISTICS: A dedicated GAF medical concierge meets all patients and attendants at the arrival terminal with a pre-arranged, air-conditioned private vehicle. For post-CABG or high-acuity patients, a wheelchair-accessible vehicle or medical-grade transport with a trained attendant is arranged on request. All follow-up transfers between accommodation and the hospital for outpatient reviews are managed by GAF's ground logistics team. DEDICATED MEDICAL INTERPRETERS: GAF maintains a multilingual coordinator network covering Arabic, Russian, French, Swahili, Bengali, and 12 additional languages. A language-matched case coordinator is assigned to every patient for the full duration of their stay, attending ward rounds and physician consultations to ensure zero communication gaps. ATTENDANT ACCOMMODATION: GAF arranges serviced apartments or hospital-affiliated guest houses within 1–3 km of all partner hospitals, offering flexible stays from 1 week to 2 months. For CABG patients requiring 4–6 weeks in-country recovery, GAF negotiates discounted extended-stay rates with verified accommodation partners. Attendant meal arrangements, local SIM cards, and guided orientation to local pharmacies for medication procurement are included in the GAF concierge package. CARE COORDINATION: A dedicated GAF patient coordinator acts as the single point of contact between the patient, the hospital billing department, the surgical team's secretariat, and the patient's home-country physician — ensuring medical records, discharge summaries, imaging CDs, and fit-to-fly certificates reach all parties promptly.
Частые вопросы о процедуре «Coronary Artery Disease Treatment»
What is the cost of Coronary Artery Disease Treatment in India compared to the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after Coronary Artery Disease Treatment?
What is the success rate of Coronary Artery Disease Treatment at GAF Healthcare's partner hospitals?
Как GAF Healthcare помогает выбрать лучшую больницу для «coronary artery disease treatment» в Ченнаи, Индия
Найдите лучшие больницы для «coronary artery disease treatment» в Ченнаи, Индия
На этой странице представлено 8 больниц в Ченнаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Coronary Artery Disease Treatment» в Ченнаи, Индия
Сколько больниц направления «Кардиоторакальная и сосудистая хирургия» представлено в Ченнаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Ченнаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Coronary Artery Disease Treatment» в Ченнаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.